Redefining cancer treatment with
Next-generation bispecific & multispecific antibodies.
Disruptive innovation in immunotherapy of Cancer, based on proprietary BiXAb® bispecific and multispecific antibody technologies.
Introduction
Breakthrough Antibody-Based Therapies in Immuno-Oncology.
BIOMUNEX Pharmaceuticals is a biopharmaceutical specializing in the discovery and development of innovative therapeutic approaches based on solid data and, biological and clinical evidence to address unmet medical needs in oncology.
Key figures
+10
Years of discovery and development in oncology
3
Strategic out-licensing deals (Ipsen, Onward Therapeutics, Sanofi)
+10
BiXAb® programs in clinical (in collaboration), or preclinical or late discovery
2
Disruptive platform technologies : BiXAb® multi-specific antibody technologies and MAIT engagers
At the Core of Our Innovation:
BiXAb® Platform Technologies
BiXAb® is our proprietary next-generation platform technologies, designed to generate innovative bispecific & multispecific antibodies.
A large panel of bispecific antibodies
BiXAb® enables the simple, rapid, and cost-efficient generation of bispecific antibodies from any pair of monoclonal antibodies as building blocks.
Industry validation
Our platform technologies have already been validated through strategic collaborations and licensing agreements with leading industry players.
Partnering
Trusted by Leading Partners
Flagship Program
BiXAb-MAIT Engagers
Our proprietary flagship program, the BiXAb-MAIT engagers, uses the BiXAb platform technologies with bispecific antibodies.
Identifies & mobilizes MAIT cells
Identify, mobilize, and bridge MAIT cells (Mucosal-Associated Invariant T-cells), present throughout the body and particularly in mucosal and barrier tissues.
Bridges immune cell to tumor
Specifically engage and kill cancer cells in solid tumors by bridging immune cells to tumor targets.
Designed to avoid key toxicities
Are expected to overcome key limitations of current CD3+ T-cell engagers (TCEs), including activation of regulatory T-cells (Tregs) and cytokine release syndrome — serious side effects that are difficult to manage for cancer patients.
MAIT cells are present throughout the body, especially in mucosal tissues where solid tumors develop. Our BiXAb-MAIT engagers are designed to recruit and redirect them to attack cancer cells with high precision, addressing a significant unmet medical need in oncology.
Our key BiXAb antibody Platform technologies.
BiXAb® Platform Technologies
Best-in-class, proprietary platform technologies enabling the discovery and development of next-generation bispecific & multi-specific antibodies for cancer treatment.
MAIT Engagers
Biomunex’s unique therapeutic approach designed to engage MAIT cells to target and kill cancer cells with high specificity.
Other Bispecific Antibodies (BsAb)
A broad and expanding pipeline of BiXAb® bispecific and multi-specific antibodies for disruptive innovation.
About
Understand our technology in 3 questions to Biomunex’s management Team
Pierre-Emmanuel Gerard, Founder, President & CEO and Simon Plyte, CSO